---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-028820"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2025-06-02T23:59:59+00:00"
generated_at: "2026-05-20T02:37:30.306683+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Esperion shareholders approve 6.25M share increase to 2022 stock plan

## Summary
- Shareholders approved amendment to 2022 Stock Option and Incentive Plan, increasing authorized shares by 6,250,000.
- Class III directors Jay P. Shepard (75.8M for) and Seth H.Z. Fischer (83.3M for) elected to board until 2028.
- Advisory vote on executive compensation passed with 70.8M for, 26.7M against, 1.5M abstain.
- Ratification of Ernst & Young as independent auditor for FY2025 approved: 118.2M for, 16.1M against.
- Shares outstanding as of record date: 198,149,421; quorum of 136,468,661 shares present.

## SEC filing metadata
- accession: 0001628280-25-028820
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2025-06-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000162828025028820/0001628280-25-028820-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000162828025028820/espr-20250529.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-028820
- JSON: https://secwatch.observer/filing/0001628280-25-028820.json
- Plain text: https://secwatch.observer/filing/0001628280-25-028820.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.